Introduction {#Sec1}
============

Cardiac channelopathies are genetic disorders associated with an increased risk of ventricular arrhythmia and sudden death (SD) in young individuals with a structurally normal heart. They include long QT syndrome (LQTS), Brugada syndrome (BrS) as well as other more rare diseases such as short QT syndrome (SQTS), early repolarisation syndrome (ERS), idiopathic ventricular fibrillation (IVF) and short-coupled torsades de pointes (scTdP)^[@CR1]^. An important aspect of arrhythmia pathophysiology in these syndromes is the precise handling of cytoplasmic calcium concentration during the excitation-contraction (EC) coupling. One the most important effectors of this EC coupling is the L-type voltage-gated calcium channel Ca~v~1.2 the main isoform expressed in ventricular cardiomyocytes. Its activation leads to an inward calcium current counterbalancing potassium outward current and (1) hence contributes to action potential plateau phase and (2) triggers the calcium-induced calcium-release phenomenon leading to the rapid increase of cytosolic calcium concentration and the contraction of cardiomyocytes^[@CR2]^. Slight alterations in the calcium concentration during EC coupling could exert a great impact on arrhythmia vulnerability^[@CR3]^.

Ca~v~1.2 is a multi-subunit complex composed of a pore-forming subunit Ca~v~α~1c,~ and auxiliary subunits including Ca~v~β~2~, and Ca~v~α~2~δ~1~^[@CR4]^. Ca~v~β~2~ and Ca~v~α~2~δ~1~, encoded by the *CACNB2* and *CACNA2D1* genes, respectively, regulate the gating properties and Ca~v~1.2 trafficking^[@CR5]--[@CR8]^. The Ca~v~β~2~ subunit binds to Ca~v~α~1c~ DI-DII loop and promotes the cell surface density of Ca~v~1.2 channels by preventing their degradation by the ubiquitin/proteasome system^[@CR9],[@CR10]^. Co-expression of the Ca~v~α~2~δ auxiliary subunit with Ca~v~β increases the calcium current and hyperpolarises the voltage of Ca~v~1.2 activation^[@CR11]^. Ca~v~α~1c~, encoded by the *CACNA1C* gene, comprises four transmembrane domains (DI to DIV) connected by cytoplasmic loops and a large intracellular C-terminal domain. The C-terminal part is a major site of regulation of Ca~v~1.2 channel, not only because it is the target site for many regulatory proteins but also due to the auto-inhibition activity of its distal C-terminal part (DCT). *In vivo*, most of the Ca~v~α~1c~ subunit (80%) is cleaved at position 1770, releasing the DCT which acts as an auto-inhibitor peptide on Ca~v~1.2 *via* its non-covalent interaction with the proximal C-terminal (PCT) part^[@CR12],[@CR13]^. Interestingly, despite the fact that the non-cleaved and the cleaved DCT have been shown to promote an auto-inhibitory effect on the calcium current (I~Ca~), Hulme *et al*. showed that the cleaved DCT has a stronger auto-inhibitory effect on I~Ca~ than the non-cleaved one^[@CR12]^. Knock-in mice expressing Ca~v~α~1c~ with a deleted DCT present perinatal mortality due to heart failure emphasises the fact that the DCT part of L-type calcium channel is primordial for normal cardiac development and function^[@CR14],[@CR15]^. In addition to the loop between DI and DII of Ca~v~α~1c~ which is known to be crucial for the channel inactivation gate, Brunet *et al*. showed that the auto-inhibitory complex could also increase the voltage-dependent inactivation of Ca~v~1.2, further decreasing the calcium influx^[@CR16],[@CR17]^. The non-covalent interaction between the PCT and the DCT leading to the decrease of I~Ca~ has been shown to be calcium-dependent and modulated by calmodulin (CaM)^[@CR13]^. In presence of low intracellular calcium, the interaction between the PCT and DCT will lead to a decrease of the open probability of Ca~v~1.2. The increase in cytoplasmic calcium will allow the complex Ca^2+^-CaM to interact with the CDD domain localised at the DCT and the IQ and pre-IQ domain from the PCT. This interaction will disrupt the PCT-DCT complex and relieve the auto-inhibition leading to an increase of I~Ca~^[@CR13]^.

*CACNA1C* was the first gene involved in a multisystem disorder called Timothy syndrome (TS)^[@CR18]^. Functional analysis of TS variants highlighted two different mechanisms triggering the severe QT interval prolongation and lethal arrhythmia observed in these patients. Missense variants localised at the C-terminal end of DI-S6 induce a nearly complete loss of Ca~v~1.2 voltage-dependent inactivation (VDI) and prolongation of the plateau phase of cardiac action potential while others variants identified in the DIII-DIV loop induced a gain-of-function by increasing the "window" current^[@CR19]^. Gain-of-function Ca~v~α~1c~ variants were also identified in the DI-DII loop in non-syndromic LQTS patients through an increase in channel surface membrane expression^[@CR20]^. Furthermore, loss-of-function variants often associated with a shortening of the plateau phase of the action potential in the three Ca~v~1.2 subunits have been reported in patients with BrS with or without short QT^[@CR21],[@CR22]^, ERS^[@CR23]^, SQTS^[@CR24]^, and sudden unexplained death in the young (SUDY)^[@CR22],[@CR25],[@CR26]^. Different molecular mechanisms were described, such as reduced current density due to impaired channel trafficking for the Ca~v~α~1c~-A39V^[@CR21]^, activation or inactivation curve shifts for Ca~v~β~2b~-S481L^[@CR21]^ and SQTS-Ca~v~α2δ1-S755T^[@CR24]^ or a marked increase in Ca~v~1.2 inactivation rate for Ca~v~β~2b~-T11I^[@CR27]^. These variants have been associated with phase 2 re-entry^[@CR28],[@CR29]^ or focal activation/re-entry from/within the Purkinje fibres^[@CR30]^. However, the fact that rare heterozygous missense variants were also present in the healthy populations questioned the implication of variants with experimentally unconfirmed pathogenicity in these diseases^[@CR31],[@CR32]^.

Thus, there is a clear need to explore the function of new Ca~v~1.2 variants to gain a better understanding of the link between these variants and life-threatening ventricular arrhythmias. As a result, we sought to identify new variants of Ca~v~1.2 genes in a cohort of 65 patients, affected by inherited arrhythmia syndrome potentially related to calcium handling and to elucidate their functional consequences.

Results {#Sec2}
=======

We screened the genes encoding the three subunits of Ca~v~1.2, *CACNA1C*, *CACNB2*, and *CACNA2D1* in 65 patients with BrS, SQTS, ERS, IVF or scTdP patients. Among them, 47 (72%) had syncopes or cardiac arrest (43%) and, 21 had a familial history of syncope or SD (32%) (Table [1](#Tab1){ref-type="table"}).Table 1Clinical characteristics of the patient cohort.BrSSQTSERSIVFscTdPProbands (male)25 (22)7 (7)7 (7)7 (4)19 (8)Symptomatic12 (48%)3 (42%)7 (100%)7 (100%)19 (100%)Resuscitated cardiac arrest3 (12%)1 (14%)6 (86%)7 (100%)11 (58%)Mean age at first symptoms (years) ±SD38.8 ± 14.225.3 ± 3.833.8 ± 4.346.1 ± 12.632.9 ± 10.9Mean age at clinical diagnosis (years) ±SD45.0 ± 12.431.1 ± 5.737.8 ± 3.249.7 ± 10.633.7 ± 10.1Family history of syncopes or SD7 (28%)6 (71%)1 (14%)1 (14%)6 (32%)Spontaneous BrS type 1 pattern15 (62.5%)0000QTc (ms)364 ± 3332 ± 3384 ± 10409 ± 20403 ± 31

In addition to frequent polymorphisms (MAF \> 1% in all populations), we identified a number of less frequent missense variants of unknown significance (VUS) in the coding sequence of *CACNA1C* in patients affected by BrS, ERS or IVF. No variants were found in *CACNB2* or *CACNA2D1*. We performed functional analyses of missense variants identified in the patients described below.

Patients and variants {#Sec3}
---------------------

### Six *CACNA1C* variants were found in 5 patients (7.7%) {#Sec4}

Case 1: This man had an aborted SD at the age of 27 when playing soccer (Fig. [1A](#Fig1){ref-type="fig"}). All investigations were negative (Holter recording, MRI, coronary angiography, isoprenaline and ajmaline tests). The only aetiology found was an early repolarisation pattern in ECG inferior and lateral leads during the days after resuscitation (Fig. [2A,B](#Fig2){ref-type="fig"}). An automatic implantable cardio defibrillator (ICD) was implanted, and the patient experienced only very short sustained episodes of ventricular tachycardia that were not treated by the ICD during the following years. This patient, of Franco-Cameroonian origin, was part of a family with no other cardiac events. He was the only one with an ERS pattern and carrying a missense variant, p.Thr1787Met (Ca~v~α~1c~-T1787M), localised in the C-terminal domain of Ca~v~α~1c~ calcium channel subunit (Fig. [1A](#Fig1){ref-type="fig"} and Supplementary Fig. [S1C](#MOESM1){ref-type="media"}). The threonine residue at position 1787 is conserved through evolution among many species but is replaced by an alanine in horse and dog (Supplementary Fig. [S2](#MOESM1){ref-type="media"}). The methionine substitution is considered as probably damaging according to Polyphen2 and the DANN Score. Ca~v~α~1c~-T1787M has a minor allele frequency (MAF) of 0.12% according to ExAC database, but it was in fact mostly found in Africans, both in the heterozygous state in 113 of 3565 individuals, and in the homozygous state in one subject (Table [2](#Tab2){ref-type="table"}). As expected, it was absent from our Caucasian control population. Another variant, p.Gly1795Arg (G1795R), with a higher frequency (MAF = 0.54% according to ExAC) was also found in this subject. His healthy son only carried the latter variant, which is frequent in Africans (MAF = 7%), and is therefore considered as likely benign (Supplementary Fig. [S1D](#MOESM1){ref-type="media"}).Figure 1Family pedigrees of Cases 1 to 5 (**A**--**E**) with the members carrying *CACNA1C* variants. The probands are indicated by an arrow. Males are represented by squares, females by circles, affected subjects by filled symbols, and healthy subjects by open symbols. Ca~v~α~1c~ missense variants or their absence (no) are indicated below each subject that has been genotyped.Figure 2Electrocardiograms of Cases 1 and 2. Case 1, (**A**) just after reanimation showing early repolarisation pattern, (**B**) 5 years later. Case 2, (**C**) short-coupled torsades de pointes, (**D**) short-coupled premature ventricular beats.Table 2*CACNA1C* variants.Case n°1 and 21 (ERS)2 (scTdP)3 (scTdP)4 (BrS)5 (scTdP)Genomic location Chr12 (GRCh38)267971226797352688637267720726778412688580NM_000719c.DNA variationc.5360 C \> Tc.5383 G \> Ac.5975 G \> Tc.4942 G \> Ac.5065 G \> Ac.5918 G \> Aprotein variationT1787MG1795RC1992FA1648TA1689TR1973QNM_199460c.DNA variationc.5504 C \> Tc.5527 G \> Ac.6224 G \> Tc.5086 G \> Ac.5209 G \> Ac.6167 G \> Aprotein variationT1835MG1843RC2075FA1696TA1737TR2056QMAFExAC (All) (%)0.120.540.010.0080.00310.36ExAC (Africans) (%)1.617.030.05000.02ISB Kaviar 3 (%)0.120.390.0080.0060.00260.31PathogenicityPolyphen 2Probably damaging: 0.993Benign: 0.001Probably damaging: 0.998Possibly damaging: 0.948Possibly damaging: 0.949Probably damaging: 0.977Mutation TasterPolymorphismPolymorphismDisease causingDisease causingDisease causingDisease causingClinVarBenign- Likely benignBenign- Likely benignUncertain significanceUncertain significanceUncertain significanceConflicting interpretations of pathogenicityDANN Score0.99660.98920.98720.87670.99820.8254

Case 2: This woman had syncope at rest at the age of 43 years, followed by a resuscitated cardiac arrest during hospitalisation with the detection of scTdP originating from Purkinje fibres (Fig. [2C](#Fig2){ref-type="fig"}). The origins of her family are from La Reunion, where four SD of unknown aetiology occurred in young children (Fig. [1B](#Fig1){ref-type="fig"}). A coronary angiography and echocardiography excluded ischaemic or structural abnormalities. She received an ICD and a verapamil treatment of 240 mg twice a day. A right ventricular scintigraphy performed at the age of 49 did not reveal any signs of arrhythmogenic right ventricular cardiomyopathy (ARVC). During the follow-up period, several asymptomatic non-sustained ventricular tachycardia events were recorded by the ICD, beginning with premature ventricular beats (PVB) with short coupling intervals (320 ms) (Fig. [2D](#Fig2){ref-type="fig"}). When she skipped her verapamil treatment, non-sustained ventricular tachycardia with a feeling of faintness and palpitation was also recorded. Electrocardiographic screening of the other family members did not show any abnormalities.

The proband carried two variants in *CACNA1C*, Ca~v~α~1c~-T1787M and p.Cys1992Phe (C1992F) (Fig. [1B](#Fig1){ref-type="fig"}, Supplementary Fig. [S1C](#MOESM1){ref-type="media"},[F](#MOESM1){ref-type="media"}). The first variant, Ca~v~α~1c~-T1787M, was the same as in the previous family. The second *CACNA1C* variant, C1992F, was found in East Asians (7/8536 alleles) and Africans (5/8536 alleles) with an overall MAF of 0.01% in ExAC. The cysteine residue at position 1992 in Ca~v~α~1c~ is highly conserved among species (Supplementary Fig. [S2](#MOESM1){ref-type="media"}) and its substitution with a phenylalanine is considered as probably damaging according to Polyphen2, Mutation Taster and the DANN Score (Table [2](#Tab2){ref-type="table"}). This variant is also located in the C-terminal region of the channel subunit. By genotyping some family members, we found that the proband was the only carrier of two variants in Ca~v~1.2 calcium channel subunits; other family members who have been genotyped were only carriers of one of these two variants.

Three additional VUS were identified in the proband: p.Leu618Phe (L618F) in the cardiac sodium channel (*SCN5A*, NM_198056, c.1852C \> T) with an overall MAF of 0.057%, and two variants in desmosomal proteins known to be associated with ARVC: p.Asn1865Trp (N1865W) in desmoplakin (*DSP*, NM_004415.2, c.5593 A \> T), with a frequency of 0.051%, and p.Val842Ile (V842I) in plakophilin 2 (*PKP2*, NM_004572, c.2524 G \> A), with an MAF of 0.0049% (Supplementary Fig. [S3](#MOESM1){ref-type="media"}).

Case 3: This patient comes from a French family where several SD occurred in young adults (Fig. [1C](#Fig1){ref-type="fig"}). She had a resuscitated cardiac arrest after lunch and her ECG showed scTdP, possibly originating from Purkinje tissue. Her own mother had died at the age of 25 during the night. Her daughter also had ventricular fibrillation originating from the Purkinje network and numerous scPVB episodes at the age of 15 years. An ICD was implanted and catheter ablation performed. A *CACNA1C* missense variant, p.Ala1648Thr (A1648T), was detected in the affected mother and daughter (Fig. [1C](#Fig1){ref-type="fig"} and Supplementary Fig. [1A](#MOESM1){ref-type="media"}). The alanine residue at position 1648 is located in a well conserved region of the protein (Supplementary Fig. [S2](#MOESM1){ref-type="media"}) and its substitution with a threonine was considered as possibly damaging according to several prediction tools (Table [2](#Tab2){ref-type="table"}). The variant was only found in 10 Europeans (10/70496 alleles) with an overall frequency of 0.01% according to the ExAC database.

Case 4: This French patient presented an aborted SD at the age of 21 during exercise, without any aetiology. Echocardiography and cardiac MRI did not show any morphological abnormality, and a stress test did not show any argument in favour of a catecholaminergic tachycardia. His basal ECG was normal and ajmaline test was negative. The patient was implanted with an ICD without other medical treatment. During the follow-up, the ICD delivered several appropriate shocks on ventricular tachycardia. At the age of 26 years, a second ajmaline test was performed and was positive. There was no family history of syncope or cardiomyopathy. A *CACNA1C* variant was identified, p.Ala1689Thr (A1689T), affecting an alanine that is well conserved during evolution (Fig. [1D](#Fig1){ref-type="fig"}, Supplementary Figs [S1B](#MOESM1){ref-type="media"} and [S2](#MOESM1){ref-type="media"}). This variant was absent from our Caucasian control population and considered as possibly damaging according to Polyphen2, Mutation Taster and the DANN Score (Table [2](#Tab2){ref-type="table"}).

Case 5: Two sisters originating from La Reunion Island were diagnosed with IVF associated with scTdP. Their great aunt, who had episodes of syncope, died suddenly at age 50. The first sister had two consecutive syncopal episodes and resuscitated cardiac arrest at age 39 with scTDP (300 msec). Subsequently, she was implanted with an ICD. She experienced an appropriate shock one year after implantation and presented an electrical storm three years after. Her sister had a first syncope during fever at 36 and then later complained of palpitations. She presented scPVB (320 msec) at ECG and scTdP (260 msec) was detected on Holter recording during palpitations. She was implanted with an ICD at age 45, but never experienced appropriate shocks. The two sisters were treated with verapamil. They both carry the same *CACNA1C* variant, p.Arg1973Gln (R1973Q) (Fig. [1E](#Fig1){ref-type="fig"} and Supplementary Fig. [S1E](#MOESM1){ref-type="media"}). The arginine residue at position 1973 of Ca~v~α~1c~ is highly conserved among species (Supplementary Fig. [S2](#MOESM1){ref-type="media"}) and is located within the Ca~v~α~1c~ C-terminal domain. The glutamine substitution was considered as probably pathogenic according to Polyphen2, Mutation Taster and the DANN Score. However, this variant was present in all ethnic populations in the ExAC database with an overall MAF of 0.36% (Table [2](#Tab2){ref-type="table"}).

Loss-of-function of the Ca~v~α~1c~-T1787M variant in *CACNA1C* {#Sec5}
--------------------------------------------------------------

The six C-terminal variants, A1648T, A1689T, T1787M, G1795R, R1973Q, and C1992F were introduced by mutagenesis in the Ca~v~α~1c~ subunit. Functional patch-clamp studies showed that, despite a slight shift in steady-state inactivation for the variants A1648T and A1689T in the presence of extracellular calcium, only the Ca~v~α~1c~-T1787M variant leads to a decrease in I~Ca~ and barium current (I~Ba~) compared to the wild-type (WT). No major alteration of the main biophysical properties was found for Ca~v~α~1c~-T1787M (steady-state activation and inactivation) (Figs [3](#Fig3){ref-type="fig"}--[4](#Fig4){ref-type="fig"}, Supplementary Figs [S4](#MOESM1){ref-type="media"}--[S9](#MOESM1){ref-type="media"}, Tables [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"}). Immunoblotting studies showed no alterations in calcium channel subunit expression after the over-expression of Ca~v~α~1c~-T1787M (Supplementary Fig. [S10A](#MOESM1){ref-type="media"}). Moreover, biotinylation of cell surface proteins showed that the surface expression of WT or Ca~v~α~1c~-T1787M was not significantly different (113 ± 11 vs 94 ± 17%, respectively, n = 3 experiments) (Supplementary Fig. [S10B](#MOESM1){ref-type="media"}).Figure 3Loss-of-function of Ca~v~α~1c~-T1787M variant: calcium currents (I~Ca~). (**A**) Representative whole-cell I~Ca~ traces showing the decrease of current density with the Ca~v~α~1c~-T1787M variant compare to WT. (**B**) Current-voltage relationships in cells transfected with either WT (○) or Ca~v~α~1c~-T1787M variants (●) of calcium channels (\**p* \< 0.05). (**C**) Steady-state inactivation and activation curves of either WT (white symbol) or Ca~v~α~1c~-T1787M variants (back symbol) of calcium channels showing no major alterations. (**D**) Calcium-dependent inactivation (CDI) with either WT (○) or Ca~v~α~1c~-T1787M variants (●) of calcium channels showing no alterations. The number of cells is indicated in parentheses.Figure 4Loss-of function of Ca~v~α~1c~-T1787M variant: barium currents (I~Ba~). (**A**) Representative whole-cell I~Ba~ traces showing the decrease of current density with the Ca~v~α~1c~-T1787M variant compare to WT. (**B**) Current-voltage relationships in cells transfected with either WT (○) or Ca~v~α~1c~-T1787M variants (●) of calcium channels (\**p* \< 0.05). (**C**) Steady-state inactivation and activation curves of either WT (white symbol) or Ca~v~α~1c~-T1787M variant (back symbol) of calcium channels showing no major alterations. (**D**) Voltage-dependent inactivation (VDI) with either WT (○) or Ca~v~α~1c~-T1787M variant (●) of calcium channels showing an increase of the VDI (\**p* \< 0.05 and \*\**p* \< 0.01). The number of cells is indicated in parentheses.Table 3Biophysical parameters of Ca~v~1.2 variants with calcium.Normalized maximum peak currentActivationSteady-state inactivation%V~1/2~ (mV)KV~1/2~ (mV)KWT100 ± 18 (19)15.45 ± 1.64 (19)7.92 ± 0.73 (19)−30.43 ± 1.05 (15)12.96 ± 0.79 (15)A1648T128 ± 15 (5)15.45 ± 2.29 (5)8.41 ± 0.24 (5)**−34.40 ± 1.56 (5)\***14.73 ± 0.70 (5)A1689T112 ± 46 (7)12.84 ± 1.31 (7)8.01 ± 0.22 (7)**−24.11 ± 0.69 (7)\***13.61 ± 0.65 (7)T1787M**48 ± 14 (6)\***11.86 ± 1.89 (6)8.19 ± 0.31 (6)−29.90 ± 1.04 (15)13.73 ± 0.67 (15)G1795R94 ± 54 (5)11.68 ± 1.80 (5)8.23 ± 0.63 (5)−25.73 ± 1.71 (7)14.33 ± 0.67 (7)R1973Q135 ± 28 (6)12.29 ± 0.97 (7)7.87 ± 0.13 (7)−25.61 ± 1.29 (9)13.21 ± 0.86 (9)C1992F109 ± 30 (6)12.21 ± 1.04 (7)7.94 ± 0.18 (7)−25.84 ± 1.64 (6)12.69 ± 0.57 (6)Activation and steady-state inactivation parameters (see material and methods) of WT and variants of Ca~v~1.2 channels. In bold, values significantly different from WT (\**p* \< 0.05). The number of cells is indicated in parentheses.Table 4Biophysical parameters of Ca~v~1.2 variants with barium.Normalized maximum peak currentActivationSteady-state inactivation%V~1/2~ (mV)KV~1/2~ (mV)KWT100 ± 10 (46)−7.49 ± 0.42 (35)6.18 ± 0.13 (35)−35.74 ± 1.01 (43)12.24 ± 0.96 (43)A1648T92 ± 20 (10)−6.53 ± 0.73 (11)5.83 ± 0.20 (11)−37.93 ± 1.45 (9)11.68 ± 0.24 (9)A1689T94 ± 25 (10)−9.14 ± 0.80 (5)6.06 ± 0.11 (5)−33.67 ± 1.20 (6)7.54 ± 0.40 (6)T1787M**28 ± 16 (8)\***−5.53 ± 1.63 (15)5.84 ± 0.45 (15)−32.93 ± 2.50 (10)9.18 ± 0.80 (10)G1795R93 ± 7 (8)−6.35 ± 0.90 (10)6.08 ± 0.18 (10)−37.35 ± 1.59 (10)12.43 ± 0.63 (10)R1973Q90 ± 14 (20)−7.31 ± 0.46 (18)6.09 ± 0.13 (18)−37.60 ± 0.76 (19)11.77 ± 0.31 (19)C1992F97 ± 12 (19)−6.23 ± 0.73 (17)5.93 ± 0.12 (17)−35.70 ± 0.74 (16)12.67 ± 0.39 (16)A1770\*100 ± 10 (21)−12.29 ± 0.75 (20)5.61 ± 0.16 (20)−38.77 ± 1.13 (21)9.96 ± 0.42 (21)A1770\*/WT64 ± 9 (24)−9.30 ± 0.70 (24)5.94 ± 0.16 (24)−39.31 ± 0.72 (24)10.32 ± 0.41 (24)A1770\*/T1787M39 ± 6 (23)\*−9.39 ± 0.88 23)6.18 ± 0.18 (23)−38.61 ± 1.22 (23)10.95 ± 0.47 (23)Activation and steady-state inactivation parameters (see material and methods) of WT, variants, and truncated constructs of Ca~v~1.2 channel. In bold: WT vs Ca~v~α~1c~-T1787M and underlined A1770\*/WT vs A1770\*/T1787M (\**p* \< 0.05). The number of cells is indicated in parentheses.

Interestingly, while the calcium-dependent inactivation (CDI) was not altered by the different variants (Fig. [3D](#Fig3){ref-type="fig"}, Supplementary Fig. [S11](#MOESM1){ref-type="media"}), the voltage-dependent inactivation (VDI) was significantly increased in the presence of the Ca~v~α~1c~-T1787M variant only (Fig. [4D](#Fig4){ref-type="fig"}, Supplementary Fig. [S12](#MOESM1){ref-type="media"}).

The inhibition mediated by the cleaved CT part on the CT-cleaved Ca~v~α~1c~ construct is stronger when the Ca~v~α~1c~-T1787M variant is present {#Sec6}
-----------------------------------------------------------------------------------------------------------------------------------------------

Since no modification of the main biophysical properties of the Ca~v~α~1c~-T1787M and a normal expression at the membrane were found, another mechanism should explain the observed reduced current density. Interestingly, the variant is localised close to the *in vivo* proteolytic cleavage site (A1770) at the beginning of the cleaved C-terminal (cleaved CT) involved in the auto-inhibition process of Ca~v~1.2 channel (Fig. [5](#Fig5){ref-type="fig"}). The auto-inhibition mechanism is mediated by the interaction of the proximal C-terminal regulatory domain (PCRD) localised in the PCT with the distal C-terminal regulatory domain (DCRD) present in the DCT (Fig. [5](#Fig5){ref-type="fig"}). This interaction has also been shown to be modulated by CaM *via* its interaction with the CaM-competitive domain (CCD) and the pre-IQ and IQ motif (see introduction) (Fig. [5](#Fig5){ref-type="fig"}).Figure 5Scheme of the C-terminal part of the voltage-gated calcium channel. Schematic representation modified from Lyu *et al*. 2017 showing the C-terminal domain of Ca~v~α~1c~ with EF-hand like region (EF), pre-IQ, IQ, PCRD, DCRD, and CaM-competitive domain (CCD)^[@CR62]^. The interaction between the PCRD and the DCRD forming the auto-inhibitory complex and the different sites of interaction with CaM (pre-IQ, IQ, and CCD) are depicted with dashed arrows. Asterisks correspond to human loss-of-function variants (present data, red)^[@CR22]^. The *in vivo* cleavage site by proteolysis correspond to 1764-NANINNANN-1772 in human. The scissors show the position of the truncation of Ca~v~α~1c~ subunit performed in this study (A1770, 1800 in rabbit).

To investigate whether Ca~v~α~1c~-T1787M could modulate this inhibition, a truncated construct at the *in-vivo* cleavage site has been generated (A1770\*) (Fig. [5](#Fig5){ref-type="fig"}). As already published, the current produced by the A1770\* truncated form is greater than that of the WT channel (WT: 34 ± 4 pA/pF (n = 36) and A1770\*: 100 ± 15 pA/pF (n = 21); p \< 0.05)^[@CR12]^. Barium currents mediated by this CT-cleaved Ca~v~α~1c~ form were decreased by 36 ± 9% when co-expressed with the WT-cleaved CT part with a significant shift of the steady-state activation curve (Fig. [6](#Fig6){ref-type="fig"} and Table [3](#Tab3){ref-type="table"}). However, when co-expressed with the cleaved CT part harbouring the Ca~v~α~1c~-T1787M variant, I~Ba~ was further decreased without biophysical property alterations compared to the WT-cleaved CT, suggesting that the presence of the variant increases the auto inhibition effect (−38 ± 10%, CT-cleaved Ca~v~α~1c~ + WT-cleaved CT vs CT-cleaved Ca~v~α~1c~ + T1787M-cleaved CT; p \< 0.05) (Fig. [6](#Fig6){ref-type="fig"} and Table [4](#Tab4){ref-type="table"}).Figure 6The I~Ba~ inhibition mediated by the cleaved CT part on the CT-cleaved Ca~v~α~1c~ construct is stronger when the Ca~v~α~1c~-T1787M variant is present. (**A**) Representative raw traces of I~Ba~ density recorded in presence of CT-cleaved Ca~v~α~1c~ alone or with either WT or T1787M-cleaved CT part. (**B**) I-V relationships showing the effect mediated by T1787M variant on the CT-cleaved Ca~v~α~1c~ when introduced in the cleaved CT part (\**p* \< 0.05: CT-cleaved Ca~v~α~1c~ + WT-cleaved CT *vs* CT-cleaved Ca~v~α~1c~ + T1787M-cleaved CT). The number of cells is indicated in parentheses.

Discussion {#Sec7}
==========

Calcium influx *via* the Ca~v~1.2 L-type calcium channel provides a multi-functional signal that triggers muscle contraction, controls action potential and regulates gene expression^[@CR33]^. Therefore, a dysregulation of the calcium channel function may lead to cardiac rhythm disorders. A limited number of Ca~v~1.2 variants have been studied; thus, the extent of their potential role remains unknown and requires validation by functional studies^[@CR19]^. Some mutations in the *CACNA1C* gene were first identified in Timothy syndrome, causing extreme QT prolongation and SD^[@CR18]^. The role of these gain-of-function mutations of Ca~v~1.2 in ventricular repolarisation prolongation was confirmed by the discovery of several other mutations in non-syndromic sporadic and familial LQTS cases^[@CR20],[@CR34]^. On the other hand, several missense variants in the Ca~v~1.2 subunits were reported as loss-of-function mutations in BrS, SQTS, ERS and SUDY patients^[@CR21],[@CR22],[@CR24]--[@CR26]^. The low penetrance of these variants suggests a complex genetic inheritance with an accumulation of several genetic risk factors of variable frequencies^[@CR35]^.

In this study, we aimed to identify variants in the three genes encoding Ca~v~1.2 subunits in patients affected with various kinds of arrhythmia disorders (BrS, SQTS, ERS, IVF and scTdP). We reported six missense variants in *CACNA1C*, one in a BrS patient, and the five others in patients with ERS and IVF. Our patch-clamp experiments revealed that, among the variants found in this study, the Ca~v~α~1c~-T1787M variant was the only Ca~v~α~1c~ variant to cause a significant reduction in I~Ca~ and I~Ba~. Barium current recordings also showed an increase in VDI for the Ca~v~α~1c~-T1787M variant compared to WT. Since I~Ca~ is involved in the cardiac action potential plateau phase, an increase in Ca~v~1.2 VDI combined with a decrease in I~Ca~ would lead to a shorter plateau phase and thus a shorter action potential. Interestingly, the QTc intervals of Cases 1 and 2 were relatively short (358 ms and 380 ms, respectively). Several other mutations (E1829_Q1833dup, Q1916R, V2014I) linked to BrS or ERS patients have been reported in this region, flanked by the PCRD and the DCRD, also leading to a loss-of-function (Fig. [5](#Fig5){ref-type="fig"})^[@CR21]--[@CR23]^. The E1829_Q1833dup, close to the Ca~v~α~1c~-T1787M variant, induced a drastic decrease in the calcium current amplitude. Unfortunately, the molecular mechanism of this loss-of-function is not known.

The C-terminal part of Ca~v~α~1c~ subunit serves as a scaffold for the targeting and localisation of signalling molecules including calmodulin^[@CR36]^, calmodulin-dependent protein kinase II^[@CR37]^, PKA and its anchoring proteins AKAP15^[@CR38]^. In addition, this C-terminal domain has also been shown to be cleaved *in vivo*^[@CR12]^.This mechanism will allow the DCRD, from the cleaved CT, to non-covalently bind to the PCRD of the CT-cleaved Ca~v~α~1c~ in order to form a complex^[@CR12]^. Finally, this complex has been shown to decrease the open probability and modulate the coupled channel gating of Ca~v~1.2 channel leading to a global decrease of I~Ca~^[@CR12],[@CR39],[@CR40]^.

Interestingly, experiments performed in this study using the CT-cleaved Ca~v~α~1c~ construct suggest a potential role for the Ca~v~α~1c~-T1787M variant in the auto-inhibitory effect. The fact that the decrease in I~Ba~ observed in presence of WT-cleaved CT is amplified when the mutation is introduced in this cleaved CT suggests that the Ca~v~α~1c~-T1787M variant could potentially increase the interactions between the PCRD and the DCRD. Stronger interaction such as this could lead to an absence of gating coupling between Ca~v~1.2 channels, as proposed by Navedo and co-workers, and/or a greater inhibition of the barium current due to the auto-inhibitory mechanism suggested by Wei and colleagues^[@CR39],[@CR40]^. Nevertheless, further experiments should be performed to challenge these hypotheses.

The fact that only the V~1/2~ for the steady-state inactivation of the A1648T and A1689T variants were significantly shifted in the presence of extracellular calcium is surprising and could be due to an artefact of the analysis. In fact, the sigmoid curves calculated by the software do not always fit with the raw data points recorded. Based on these observations, and due to the fact that neither the peak current densities nor other biophysical parameters are altered, additional experiments are required to confirm these alterations.

Although we identified this pathogenic variant in two IVF patients, we did not find pathogenic variants responsible for BrS or SQTS in our cohort as previously reported, and two of the three variants identified in scTdP appeared to be non-functional polymorphisms. We identified six variants in *CACNA1C*, two of which, R1973Q and Ca~v~α~1c~-T1787M, have already been reported by Burashnikov *et al*. in two BrS patients and one BrS patient, respectively^[@CR22]^. The latter did not form part of those who underwent functional analyses^[@CR22]^. Measures of evolutionary sequence conservation and allele frequency are widely used as indicators of the deleteriousness of protein variation but their predictive power is limited by statistical and biological factors^[@CR41]^. Interestingly, among the identified variants, the five most conserved residues in Ca~v~1.2 Ca~v~α~1c~ were non-pathogenic and our only pathogenic variant, Ca~v~α~1c~-T1787M, was not perfectly conserved among all mammals and was found in 0.8% of Africans. Many deleterious variants do not show a strong conservation signature and conversely, strong conservation does not necessarily mean that the variant has an effect on disease risk, which is consistent with our results. Due to the relatively high frequency in Africans, the Ca~v~α~1c~-T1787M variant would initially have been excluded during exome sequencing data analysis according to classical criteria. Since it was found in two unrelated patients with ventricular fibrillation: Cases 1 and 2 originating from Cameroon and from La Reunion, an island of known mixed origin, we performed functional analysis. A strong association between early repolarisation pattern and/or sudden death was reported in several studies including Cameroonian patients^[@CR42]--[@CR44]^. As seen for a number of other ECG-derived traits, such as QT interval, an early repolarisation pattern is a heritable component^[@CR45]^.

The results presented in this study suggest that the *CACNA1C* variant Ca~v~α~1c~-T1787M is likely a potential new risk factor contributing to the development of ventricular arrhythmogenicity in Africans. The best-known African pro-arrhythmic variant is Na~v~1.5-S1103Y, which has a MAF of 13% in African Americans^[@CR46]--[@CR48]^. The Y1103 allele carriers have an inherent susceptibility to potentially lethal arrhythmias, and are frequent in cohorts of patients with SD^[@CR49]^ and Sudden Infant Death Syndrome^[@CR48],[@CR50]^. Additional factors, such as other genetic variants^[@CR51]^, medications^[@CR46]^, heart failure associated with a reduced ejection fraction^[@CR52]^, and hypokalemia associated with diuretic use^[@CR53]^ can contribute to fatal arrhythmias. Interestingly, case 1 is also a heterozygous carrier of the Na~v~1.5-S1103Y variant. The association of the two variants Ca~v~α~1c~-T1787M and Na~v~1.5-S1103Y might contribute to the patient phenotype.

In addition to the Ca~v~α~1c~-T1787M, Case 2 inherited a variant in the sodium channel, L618F, and two variants in desmosomal proteins, N1865Y in desmoplakin and V842I in plakophilin 2 from her mother. The leucine residue at position 618 is located in the I-II linker domain of the cardiac Na^+^ channel, next to L619F mutation, reported in a LQT3 child and associated with a defective inactivation, a faster recovery and an increase in window current^[@CR54]^. These two adjacent leucines are conserved in four other sodium channels (Na~v~1.1, Na~v~1.2, Na~v~1.6, Na~v~1.7), and the variant L618F is mostly found in Africans (MAF = 0.64%). A previous study reported no change in window current and late sodium current for L618F in the background of the hH1-Q1077 isoform^[@CR55]^. Nevertheless, since variant alterations may vary according to the isoform used in expression studies, we studied this variant again in the most abundant hH1a-Q1077del Na~v~1.5 isoform background^[@CR47],[@CR56]^ and confirmed the benign effect of this variant (Supplementary Fig. [S13](#MOESM1){ref-type="media"}). Accordingly, no QT prolongation was observed in the family members carrying this variant. As for the desmosomal protein variants, PKP2-V842I and DSP-N1865Y, these rare variants are both of unknown significance. They have never been reported and were found in 6/60,000 and 1/60,000 subjects in the ExAC database. MRI did not diagnose any structural abnormalities in Case 2, nor in her sisters carrying one or two of these variants. Only the mother at the age of 72 showed a mild dilatation of the right ventricle. Interestingly, some PKP2 variants have been reported to locally modify sodium channel density at intercalated disks^[@CR57]^, and the silencing of desmoplakin decreases connexin 43/Na~v~1.5 expression and sodium current in HL1 cardiac muscle cell line^[@CR58]^. The accumulation of all of these variants in a same subject may contribute to the ventricular hyperexcitability observed in Case 2.

Identifying the origin of cardiac channelopathies in patients with rare arrhythmias provides a unique opportunity to identify at risk surviving relatives and the possible prevention of future SD. This study underlined the hypothesis of a combinatory effect of several variants to explain the phenotype of the patients, especially Cases 1 and 2. Indeed, the Ca~v~α~1c~-T1787M variant may not be sufficient to cause the phenotype observed in patients, but like Na~v~1.5-S1103Y, it could play a role combined with additional risk factors.

Conclusions {#Sec8}
===========

Overall, this study shows that the Ca~v~α~1c~-T1787M variant present in 0.8% of the African population was identified in two out of 65 patients (3.1%) with resuscitated cardiac arrest. This variant causes a potentially arrhythmogenic Ca~v~1.2 loss-of-function.

Limitations of the study {#Sec9}
------------------------

Patch-clamp analysis of five of our variants did not show any abnormal Ca~v~1.2 activities. Nevertheless, based on the limitations due to the experimental model used in this investigation, we cannot exclude that those variants could lead to abnormal calcium handling in native cardiomyocytes. In fact, in cardiac cells, contrary to the TsA-201 cell line, Ca~v~1.2 channels are mainly expressed in the T-tubule structure within macro-molecular complexes allowing specific regulation of the voltage-gated calcium channel^[@CR59]^. Further investigations using another model close to cardiomyocytes such as cardiomyocytes derived from induced pluripotent stem (iPS) cells from the patients could be an alternative to decipher whether those variants are pathogenic or not.

Material and Methods {#Sec10}
====================

Patients {#Sec11}
--------

The patient cohort consisted of probands originating from different countries with BrS, SQTS, ERS, IVF and scTdP according to the international consensus criteria^[@CR1],[@CR60]^. Underlying structural heart disease was excluded by echocardiography. Laboratory tests excluded acute ischaemia and metabolic or electrolyte disturbances.

Symptomatic and asymptomatic BrS probands, displayed a BrS type-1 pattern on electrocardiogram (ECG) (ST segment elevation ≥2 mm in one or more right precordial leads), either spontaneously, or induced by a sodium blocker challenge test (ajmaline or flecainide). All were negative for mutations in *SCN5A*, *SCN1B*, *SCN2B*, *SCN3B*, *KCNJ8*, *KCNE3*, *KCND3*, and *RANGRF*.

SQTS probands had either QTc intervals inferior to 330 msec, or QTc between 330 and 360 msec with a family history of SD before the age of 40, or survival of VT/VF episode in absence of heart disease.

ERS was diagnosed in the presence of J-point elevation ≥1 mm in ≥2 contiguous inferior and/or lateral leads of a standard 12-lead ECG in patients with or without cardiac arrest from otherwise unexplained VF/polymorphic VT.

Twenty-six patients had syncopes with a normal ECG at rest and during exercise stress test. Seven of them had a resuscitated cardiac arrest and were diagnosed as IVF in absence of cardiac, respiratory, metabolic and toxicological aetiologies. Nineteen presented with scPVB or scTdP originating from Purkinje fibres confirmed by electrophysiological study and were classified as scTdP.

Blood samples were obtained after signed informed consent forms were collected for genetic analyses and upon approval of the local ethics committee of the Saint-Louis Hospital. The study was conducted according to the principles of the Helsinki Declaration.

CACNA1C, CACNB2 and CACNA2D1 analysis {#Sec12}
-------------------------------------

Genomic DNA was extracted from peripheral blood leukocytes according to standard procedures. The genes *CACNA1C (*NM_199460.3), *CACNB2 (*NM_000724.3), and *CACNA2D1* (NM_000722.3) were first screened in 2012 in 47 patients using a high-resolution melt (HRM) analysis method in a real-time PCR thermocycler (LightCycler 480^®^, Roche Diagnostics^®^). Primers were designed according to HRM specifications and permitted the amplification of all exons and splice junctions (available upon request). Results were analysed using the gene-scanning module of the LightCycler 480^®^ software (Roche Diagnostics^®^). When a new variant was identified, the PCR product was purified and sequenced with the Big Dye Terminator v.3.1 kit (Applied Biosystems^®^). Sequencing was performed on the ABI PRISM 3730 automatic DNA sequencer (Applied Biosystems^®^). Variants were identified by visual inspection of the sequence with Codon Code Aligner^®^ software (4.1.1 version). Then, the frequency of novel non-synonymous variants was evaluated by screening 300 Caucasian and 100 North African unrelated healthy controls.

In addition, a whole exome sequencing (WES) was performed in 2015 by IntegraGen (Evry, France) for 18 probands presenting IVF associated with scPVB or scTdP. Genomic DNA were fragmented by sonication and purified to yield fragments of 150--200 bp. Paired-end adaptor oligonucleotides from the NEBNext Direct kit (New England Biolabs) were ligated on repaired, tailed fragments and then purified and enriched by 8 PCR cycles. From these purified libraries, 1200 ng were then hybridised to the SureSelect oligo probe capture library (SureSelect XT Clinical Research Exome −54 Mb, Agilent) for 72 hours. After hybridisation, washing, and elution, the eluted fraction was PCR-amplified with 9 cycles, purified and quantified by QPCR to obtain sufficient DNA template for downstream applications. Each eluted-enriched DNA sample was then sequenced on an Illumina HiSeq4000 as paired-end 75b reads. Bioinformatic analyses were performed by IntegraGen. Reads were aligned with human genome assembly GRch37. The variants were filtered using IntegraGen ERIS platform.

The prediction of the amino acid substitution effect on protein structure and function was assessed using different prediction tools including Polyphen2, Mutation Taster, ClinVar and the DANN Score^[@CR61]^. The variant allele frequencies in population of various origins were obtained from the Exome Aggregation Consortium database (ExAC) (<http://exac.broadinstitute.org/>) and from the catalogue of human genomic variation, ISB release Kaviar (<https://www.systemsbiology.org/research/isb-releases-kaviar-worlds-largest-public-catalog-of-human-genomic-variation/>). Variants were numbered in the text and figures according to the sequence NM_000719.6 as most of the previous published variants.

Cav1.2 subunit expression vectors and mutagenesis {#Sec13}
-------------------------------------------------

Truncated and WT rabbit Ca~v~1.2 cardiac isoform Ca~v~α~1c~ (NM_001136522), Ca~v~β~2~ (NM_001082396.1) and Ca~v~α~2~δ~1~ (NM_001082276) complementary DNAs (cDNAs) subcloned into pCARDHE, pBH17 and pCA1S, respectively, were gifts from Dr G.S. Pitt (Department of Medicine, Division of Cardiology, Duke University Medical Center, Durham, NC, USA). Mutants were generated using the QuikChange II XL Site-Directed Mutagenesis Kit (Stratagene, USA) according to the manufacturer's instructions. Primers designed for mutagenesis are available upon request. All plasmids were checked by sequencing.

Transfections {#Sec14}
-------------

T25 cm^2^ flasks of TsA-201 cells at 80% confluency were transiently co-transfected using X-tremeGene 9^®^ mix reagent (Roche Diagnostics, IN, USA) with 0.7 µg of each subunit of voltage-gated calcium channel (Ca~v~α~1c~, Ca~v~β~2b~ and Ca~v~α~2~δ~1~ subunits, ratio1:1:1). All transfections included 0.2 µg of cDNA encoding CD8 antigen and 0.1 µg of cDNA encoding GFP as a reporter gene. For the co-expression assays using cleaved CT constructs, the fragment coding for the C-terminal part has been introduce in pIRES vector co-expressing CD8. For patch clamp experiments, anti-CD8 beads (Dynal^®^, Oslo, Norway) were used. Only cells decorated with anti-CD8 beads that were concomitantly green (GFP) were analysed.

Electrophysiology {#Sec15}
-----------------

Whole-cell currents were measured at room temperature (22--23 °C) using a VE-2 amplifier (Alembic Instrument, USA). The internal pipette solution was composed of (in mmol/L) 60 CsCl, 70 Cs-aspartate, 1 MgCl~2~, 10 HEPES, 11 EGTA and 5 Mg-ATP, pH 7.2, with CsOH. The external solution contained (in mmol/L) 130 NaCl, 5.6 CsCl, 5 BaCl~2~ or 20 mM CaCl~2~, 1 MgCl~2~, 10 HEPES and 11 D-glucose, pH 7.4, with NaOH. Data were analysed using pClamp software, version 10.2 (Axon Instruments, Union City, California, USA). Calcium and barium current densities (pA/pF) were calculated by dividing the peak current by the cell capacitance. Activation curves and steady-state inactivation curves were fitted with the following single Boltzmann equation: y = 1/(1 + exp \[(*V*h − *V*~50~)/k\]), in which *y* is the normalised conductance or peak current at a given holding potential (*V*h); *V*~50~ is the voltage at which half of the channels are activated (*V*~50~, act) or inactivated (*V*~50~, inact) respectively, and *k* is the slope factor. Calcium-dependent inactivation (CDI) and voltage-dependent inactivation (VDI) in presence of extracellular calcium or barium respectively were calculated at the percentage of current decreased at the end of the 200 ms test pulse.

Statistical analysis {#Sec16}
--------------------

Data are presented as means ± S.E.M. Unpaired, two-tailed Student's *t*-test was used to compare the means; *p* \< 0.05 was considered significant.
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